N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

Sponsor: Novo Nordisk A/S • ClinicalTrials.gov ID: NCT07745504

Registry updated: 2026-09-04
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.

Interventions

  • Cagrilintide (Drug)
    Cagrilintide will be administered subcutaneously.
  • Placebo cagrilintide (Drug)
    Placebo matched to cagrilintide will be administered subcutaneously.
  • Placebo semaglutide (Drug)
    Placebo matched to semaglutide will be administered subcutaneously.

Eligibility criteria

Inclusion criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) greater than or equal to (\>=) 30.0 kilograms per square meter (kg/m\^2), or BMI \>= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. Exclusion criteria: * History of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D). * Previous dosing of marketed or non-marketed amylin-based compounds. * Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening.

Conditions

Overweight Obesity

Locations

  • Hope Clin Res & Wellness — Conyers, Georgia, United States
  • East West Med Res Inst — Honolulu, Hawaii, United States
  • Walgreens - Store 11760 — Oak Park, Illinois, United States
  • Midwest Inst For Clin Res — Indianapolis, Indiana, United States
  • The Alliance for Multispecialty Research LLC AMR — Lexington, Kentucky, United States
  • PharmQuest — Greensboro, North Carolina, United States
  • KDCILM, LLC & Accellacare US, Inc. — Wilmington, North Carolina, United States
  • Coastal Carolina Res Ctr — North Charleston, South Carolina, United States
  • Health Res of Hampton Roads — Newport News, Virginia, United States
  • National Clin Res Inc. — Richmond, Virginia, United States
  • Selma Medical Associates — Winchester, Virginia, United States
  • General Hospital Of Athens Alexandra - Department of Endocrinology, Diabetes Center — Athens, Greece
  • General Hospital Of Athens G Gennimatas - Department of Endocrinology — Athens, Greece
  • General Hospital Venizeleio-Pananeio - Diabetic Clinic — Irakleio, Greece
  • Athens Medical Center S.A. (Iatriko Peristeriou) - Diabetes, obesity and cardiometabolic diseases department — Peristeri, Greece
  • Ippokratio General Hospital Of Thessaloniki - B' Internal Medicine clinic — Thessaloniki, Greece
  • St. Luke's Hospital S.A. - Endocrinology Department and Obesity Clinic — Thessaloniki, Greece
  • Stúdium Egészségház Kft. — Kalocsa, Bács-Kiskun county, Hungary
  • Borbánya Praxis E.Ü. Kft. — Nyíregyháza, Szabolcs-Szatmar Varmegye, Hungary
  • Trial Pharma Kft. — Kecskemét, Hungary
  • KomplexLabor Diagnosztika Kft. — Szeged, Hungary
  • ULS Do Oeste E.P.E. - Unidade Caldas da Rainha_CAMI - Unidade de Diabetes — Caldas da Rainha, Portugal
  • ULS Do Baixo Mondego, E.P.E. - HDFF_Serviço Cirurgia (Esp. Endocrinologia) — Figueira da Foz Municipality, Portugal
  • Hospital São Francisco, S.A_EECC — Leiria, Portugal
  • APDP - Associação Protectora dos Diabéticos de Portugal — Lisbon, Portugal
  • CVP Hospital Cruz Vermelha_Cardiologia — Lisbon, Portugal
  • ULS De Gaia/Espinho_H.Santos Silva_Endocrinologia — Vila Nova de Gaia, Portugal
  • Endocrinology, Diabetes and Metabolism Diseases Clinic — Belgrade, Serbia
  • Institute for Cardiovascular Diseases of Vojvodina - Sremska Kamenica — Kamenitz, Serbia
  • Clinical Centre Nis, Endocrinology, Diabetes and Metabolism — Niš, Serbia
  • University Clinical Centre Nis, Clinic for Cardiology — Niš, Serbia
  • Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis. — Novi Sad, Serbia
  • Skånes Universitets Sjukhus — Lund, Sweden
  • Forsåker vårdcentral — Mölndal, Sweden
  • Örebro US - Överviktsenheten — Örebro, Sweden
  • Dalecarlia Clinical Research AB — Rättvik, Sweden
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record